<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428554</url>
  </required_header>
  <id_info>
    <org_study_id>19 URO 15</org_study_id>
    <nct_id>NCT04428554</nct_id>
  </id_info>
  <brief_title>Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy</brief_title>
  <acronym>BLAD-RAD01</acronym>
  <official_title>Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, multicenter, randomized open-label and comparative study designed to&#xD;
      evaluate whether local consolidative radiotherapy plus standard of care improves overall&#xD;
      survival as compared to standard of care in patients with limited metastatic urothelial&#xD;
      bladder cancer and without progression following the initial phase of first-line systemic&#xD;
      therapy.&#xD;
&#xD;
      Each patient will be followed during 4 years from the date of randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>4 years for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by the toxicity grading of the National Cancer Institute (NCI-CTCAE v5)</measure>
    <time_frame>4 years for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be evaluated by the EORTC QLQ-C-30 questionnaire</measure>
    <time_frame>4 years for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Urothelial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Experimental arm</intervention_name>
    <description>Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          3. Urothelial bladder cancer histologically proven (both pure urothelial cancers and&#xD;
             mixed histologic features are allowed)&#xD;
&#xD;
          4. Metastatic patients (AJCC v8: M1a or M1b) documented with contrast-enhanced CT-scanner&#xD;
             of the chest, abdomen and pelvis, either de novo or presenting first distant relapse&#xD;
             following cystectomy (with no local recurrence in the cystectomy bed) more than 6&#xD;
             months after completion of peri-operative chemotherapy&#xD;
&#xD;
          5. Completion of the initial phase (4-6 cycles) of 1st line metastatic treatment&#xD;
             (systemic therapy by chemotherapy and/or immunotherapy by immune check-point inhibitor&#xD;
             according to standard recommendations)&#xD;
&#xD;
          6. No disease progression after the initial phase of first-line metastatic systemic&#xD;
             therapy according to RECIST v1.1&#xD;
&#xD;
          7. No more than 3 residual metastatic lesions following the initial phase of first-line&#xD;
             metastatic systemic therapy:&#xD;
&#xD;
               1. The number of residual lesions is determined on the basis of the imaging modality&#xD;
                  for tumor response assessment performed after systemic treatment according to&#xD;
                  local habits (CT-scan or 18FDG PET-CT if performed):&#xD;
&#xD;
                  In case of response assessment by CT-scanner only: residual lesions are all&#xD;
                  remaining visible lesions&#xD;
&#xD;
                  In case of response assessment by additional 18FDG PET-CT: residual lesions are&#xD;
                  only the lesions with residual hyperfixation&#xD;
&#xD;
               2. Regarding distant lymph nodes metastases:&#xD;
&#xD;
             If evaluation is performed by CT-scanner only, residual lymph nodes are considered&#xD;
             pathological according to one or several criteria among:&#xD;
&#xD;
               -  Short axis ≥ 1cm&#xD;
&#xD;
               -  Central necrosis&#xD;
&#xD;
               -  Heterogeneous contrast enhancement&#xD;
&#xD;
             Residual para-aortic nodes involvement accounts for one lesion, even if several&#xD;
             para-aortic nodes are involved.&#xD;
&#xD;
             Other nodes: each involved node accounts for one lesion.&#xD;
&#xD;
          8. Residual metastases (if applicable) eligible for SBRT in terms of dose constraints to&#xD;
             the organs at risk, with no prior radiotherapy interfering with SBRT&#xD;
&#xD;
          9. 6 weeks or less between last cycle of systemic treatment and randomization&#xD;
&#xD;
         10. No contraindication to pelvic radiotherapy&#xD;
&#xD;
         11. Signed informed consent&#xD;
&#xD;
         12. Patient able to participate and willing to give informed consent prior performance of&#xD;
             any study-related procedures and to comply with the study protocol&#xD;
&#xD;
         13. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-transitional cell histology (Squamous cell carcinoma, adenocarcinoma or&#xD;
             neuroendocrine carcinoma of the bladder)&#xD;
&#xD;
          2. Brain metastases before systemic treatment&#xD;
&#xD;
          3. Liver metastases before systemic treatment&#xD;
&#xD;
          4. Absence of target to be irradiated (i.e. previous cystectomy + no residual lesions&#xD;
             following systemic treatment + no pelvic or para-aortic nodes at metastatic&#xD;
             presentation)&#xD;
&#xD;
          5. Patient with relapse following definitive chemoradiation of the bladder&#xD;
&#xD;
          6. Local recurrence in the cystectomy bed following cystectomy&#xD;
&#xD;
          7. Previous pelvic irradiation&#xD;
&#xD;
          8. Prior radiotherapy near the residual metastatic lesions precluding ablative SBRT&#xD;
&#xD;
          9. Active inflammatory bowel disease&#xD;
&#xD;
         10. Contraindication to SBRT of a lesion due to organ dysfunction; in particular, patients&#xD;
             with lung lesions and documented or suspected interstitial lung disease should not be&#xD;
             included&#xD;
&#xD;
         11. History of scleroderma&#xD;
&#xD;
         12. Current or past history of second neoplasm diagnosed within the last 5 years (except&#xD;
             basocellular carcinoma and prostate cancer incidentally discovered during previous&#xD;
             cystoprostatectomy and pelvic lymph node dissection and with a good prognosis [T stage&#xD;
             &lt;pT3b and Gleason &lt;8 and pN- and post-operative PSA &lt;0.1 ng/mL])&#xD;
&#xD;
         13. Pregnancy or breast feeding or inadequate contraceptive measures&#xD;
&#xD;
         14. Known psychiatric or substance abuse disorders that would interfere with cooperation&#xD;
             with the requirements of the trial&#xD;
&#xD;
         15. Any psychological, familial, geographic or social situation, according to the judgment&#xD;
             of investigator, potentially preventing the provision of informed consent or&#xD;
             compliance to study procedure&#xD;
&#xD;
         16. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under legal protection (curatorship and guardianship, protection of justice)&#xD;
&#xD;
         17. Concurrent enrolment in another interventional therapeutic clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan KHALIFA</last_name>
    <phone>05 31 15 54 01</phone>
    <email>khalifa.jonathan@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent VOTRON</last_name>
      <phone>05 63 77 77 56</phone>
      <email>votron@claude-bernard-albi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie MESGOUEZ-NEBOUT</last_name>
      <phone>02 41 35 27 00</phone>
      <email>thalie.mesgouez-nebout@ico-unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul SARGOS</last_name>
      <phone>05 56 33 33 33</phone>
      <email>P.Sargos@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike SCHICK</last_name>
      <email>ulrike.schick@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MEYER</last_name>
      <phone>02 31 45 50 50</phone>
      <email>e.meyer@baclesse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica MIROIR</last_name>
      <phone>04 73 27 81 42</phone>
      <email>jessica.miroir@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Andrée Dutreix</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas MULLIEZ</last_name>
      <phone>03 28 51 96 30</phone>
      <email>thomasmulliez@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David PASQUIER</last_name>
      <phone>03 20 29 51 44</phone>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naji SALEM</last_name>
      <phone>04 91 22 36 37</phone>
      <email>salemn@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles CREHANGE</last_name>
      <phone>01 72 38 94 45</phone>
      <email>gilles.crehange@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentine GUIMAS</last_name>
      <phone>02 40 57 99 55</phone>
      <email>valentine.guimas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE</last_name>
      <phone>04 77 91 74 25</phone>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan KHALIFA</last_name>
      <phone>05 31 15 54 29</phone>
      <email>khalifa.jonathan@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre BLANCHARD</last_name>
      <phone>01 42 11 44 13</phone>
      <email>pierre.blanchard@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

